Trial Profile

An Expanded Access Program Allowing Compassionate Use of Opaganib for Patients with Confirmed SARS-CoV-2 Infection with Life-Threatening Manifestations

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Apr 2020 According to a RedHill Biopharma media release, the company is planning to convert this compassionate use program to a clinical study in order to generate more robust clinical data in a controlled setting for regulatory purposes.
13 Apr 2020 According to a RedHill Biopharma media release, patients are planned to be treated in three major hospitals in northern Italy under an expanded access program approved by the Italian National Institute for Infectious Diseases, allowing compassionate use of opaganib, for patients with confirmed SARS-CoV-2 infection with life-threatening manifestations.
08 Apr 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com